Advanced Therapies
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Advanced Therapies - overview
Established
2004
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Founded in 2004 and based in the US, Advanced Therapies, LLC. , formerly known as WuXi AppTec Group's Advanced Therapies Unit, and doing business as Advanced Therapies, operates as a provider of cell theraphy and manufacturer of viral vector products. Originally established in Wuxi, China, it became the first contract development and manufacturing organization (CDMO) to receive FDA approval to produce T-cell therapies for solid tumors. The unit has five factories in the United States and the United Kingdom.
In March 2025, Altaris acquired WuXi AppTec Group's Advanced Therapies Unit. Upon completion, the firm was rebranded as Advanced Therapies and headquartered in the United States. WuXi AppTec Group's Advanced Therapies Unit provides customers with complete cell therapy outsourcing solutions, including viral vector production, cell therapy process development and production, and biosafety testing. It also has plasmid discovery (SnapFast™), adeno-associated viral vector (TESSA®), and lentiviral vector (XOFLX™) production processes.
The company generates revenue by providing viral vector production, cell therapy process development and production, and biosafety testing.
Current Investors
Altaris
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.advancedtherapies.com/
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Advanced Therapies - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Carve Out | Completed | Advanced Therapies | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.